ASCENT-03 e ASCENT-04: il dato della PFS2 nelle pazienti con mTNBC
[Oncoinfo – Oncology Snapshots: follow us on http://oncoinfo.it] Data from ASCENT-03 and ASCENT-04 on the long-term impact of first-line sacituzumab govitecan in patients with metastatic triple-negative breast cancer were presented at ASCO 2026. Why are these practice-changing results? We discussed this with Lucia Del Mastro (Director of the Medical Oncology Clinic, IRCCS Ospedale Policlinico San Martino – University of Genoa), whom we met at the conference in Chicago.
▶︎
Cabozantinib: Managing toxicities in neuroendocrine tumors
▶︎
HCC: multidisciplinarietà e prospettive terapeutiche future
▶︎
Head and Neck Cancer: Refining and Optimizing ASCO 2026
▶︎
Lymphoma in the elderly and/or heart patients: an Italian study on non-pegylated liposomal doxoru...
▶︎
BREAKWATER trial update: confirmations and paradigm shifts
▶︎
'All of them took BOOSTERS': Witness’ explosive claim linking mRNA COVID vaccines to cancer relapse
▶︎
Chronic lymphocytic leukemia: next-generation covalent BTK inhibitor effective in patients over 80
▶︎
Ivermectin to Treat Cancer? Get the FACTS
▶︎
Small cell lung cancer with brain metastases, data on tarlatamab
▶︎
Multiple myeloma: a new quadruplet therapy that reduces relapses has been approved in Italy.
▶︎
This Isn't Experimental: The Breast Cancer Update You Missed | Cancer Drug Designer
▶︎
How Long Chemo Side Effects Really Last?
▶︎
BLOOD CANCER SPECIAL - RESEARCH IS CHANGING THE FUTURE OF TREATMENT FOR LEUKEMIA, LYMPHOMA, AND M...
▶︎
Neurologist Warns: If Your NAILS Look Like THIS After 60 Your Body May be Hiding 4 Diseases| Mandell
▶︎
Oncology Wednesdays | News from ASCO Part I - Lung cancer and rare tumors
▶︎
Repurposed drugs for cancers
▶︎
Final OS analysis of PATHWAY trial: the clinical significance
▶︎
How does chemotherapy work? A brief comparison to immunotherapy.
▶︎
Immunotherapy for cancer: Utilizing the body's natural defenses
▶︎